ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer

Tan, Peixin; Huang, Wei; He, Xinyan; Lv, Fengquan; Cui, Yanhai*; Du, Shasha*广东省人民医院; 南方医科大学
Journal of Immunotherapy2023-2DOI: 10.1097/CJI.0000000000000451
3被引6阅读
引用收藏
分享

摘要

Checkpoint inhibitor-related pneumonitis (CIP) is one of the most important immune checkpoint inhibitors side effects, and it is rare but fatal. Identifying patients at risk of refractory CIP before the start of CIP therapy is important for controlling CIP. We retrospectively analyzed the clinical data of 60 patients with lung cancer who developed CIP. Refractory CIP was defined as CIP with poor response to corticosteroid treatment, including CIP not relieved with corticosteroid administration or CIP recurrence during the corticosteroid tapering period. We analyzed clinical characteristics, peripheral blood biomarkers, treatment, and outcomes in nonrefractory and refractory CIP. Risk factors associated with refractory CIP were assessed. Among 60 patients with CIP, 16 (26.7%) had refractory CIP. The median onset time for patients with nonrefractory and those with refractory CIP was 16.57 (interquartile range [IQR], 6.82-28.14) weeks and 7.43 (IQR, 2.71-19.1) weeks, respectively. The level of lactate dehydrogenase (LDH) was significantly higher in the refractory CIP group at baseline (255 [222, 418] vs. 216 [183, 252], P=0.031) and at CIP onset (321.5 [216.75, 487.5] vs. 219 [198. 241], P=0.019). An LDH level >320 U/L at CIP onset was an independent risk factor of refractory CIP (odds ratio [OR], 8.889; 95% confidence interval [CI]: 1.294-61.058; P=0.026). The incidence of refractory CIP is high among patients with CIP. An increased LDH level at CIP onset is independently associated with refractory CIP. Monitoring LDH levels during immune checkpoint inhibitors treatment is recommended.

学科与关键词

关键词
checkpoint inhibitor-related pneumonitislung cancerimmunotherapyrefractory pneumonitis
相关
加载中…
  • Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
    Lin, Xinqing; Deng, Haiyi; Chen, Likun; Wu, Di; Chen, Xiaobo; Yang, Yilin; Chen, Tao; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Ouyang, Ming; Qin, Yinyin; Li, Shiyue; Zhong, Nanshan; Gregg, Jeffrey P.; Horita, Nobuyuki; Song, Yong*; Zhou, Chengzhi*Translational Lung Cancer Research, 2021, 10(1): 415-429.被引 12
  • Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
    Lin, Xinqing; Deng, Jiaxi; Deng, Haiyi; Yang, Yilin; Sun, Ni; Zhou, Maolin; Qin, Yinyin; Xie, Xiaohong; Li, Shiyue; Zhong, Nanshan; Song, Yong*; Zhou, Chengzhi*Frontiers in Immunology, 2022, 12: 818492.被引 13
  • Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis
    Zhou, Chengzhi; Yang, Yilin; Lin, Xinqing; Fang, Nianxin; Chen, Likun; Jiang, Juhong; Deng, Haiyi; Deng, Yu; Wan, Minghui; Qiu, Guihuan; Sun, Ni; Wu, Di; Long, Xiang; Zhong, Changhao; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Ouyang, Ming; Qin, Yinyin; Petrella, Francesco; Fiorelli, Alfonso; Bravaccini, Sara; Kataoka, Yuki; Watanabe, Satoshi; Goto, Taichiro; Solli, Piergiorgio; Igai, Hitoshi; Saito, Yuichi; Tsoukalas, Nikolaos; Nakada, Takeo; Li, Shiyue*; Chen, Rongchang*Frontiers in Immunology, 2022, 13: 935779.被引 6
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Immunotherapy
发表日期
2023-02
卷期
第 46 卷, 第 2 期
页码
64-73
DOI
10.1097/CJI.0000000000000451
语言
ENGLISH
成果收录
SCIE
资助标注
GDPH Supporting Fund for NSFC Program [8190120260]; Guangzhou Science and Technology Plan Foundation [2021-02-01-04-1002-0017]; National Natural Science Foundation of China [81972970, 82172671]; Natural Science Foundation of Guangdong Province of China [2020A1515010186]

作者

  • T

    Tan, Peixin (第一作者)

    guangdong prov peoples hosp · southern med univ

  • H

    Huang, Wei

    guangdong prov peoples hosp · southern med univ

查看全部 6 位作者收起作者
  • H

    He, Xinyan

  • L

    Lv, Fengquan

    guangdong prov peoples hosp · southern med univ

  • C

    Cui, Yanhai (通讯)

    2 · guangdong prov peoples hosp · southern med univ

  • D

    Du, Shasha (通讯)

    guangdong prov peoples hosp · southern med univ · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417